Mattox Austin K, Li Jing, Adamson David C
Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University, Durham, NC 27710, USA.
Curr Drug Discov Technol. 2012 Dec;9(4):294-304. doi: 10.2174/157016312803305924.
Glioblastoma multiforme (GBM) represents one of the most common aggressive types of primary brain tumors. Despite advances in surgical resection, novel neuroimaging procedures, and the most recent adjuvant radiotherapy and chemotherapy, the median survival after diagnosis is about 12-14 months. Targeting migrating GBM cells is a key research strategy in the fight against this devastating cancer. Though the vast majority of the primary tumor focus can be surgically resected, these migrating cells are responsible for its universal recurrence. Numerous strategies and technologies are being explored to target migrating glioma cells, with small molecular inhibitors as one of the most commonly studied. Small molecule inhibitors, such as protein kinase inhibitors, phosphorylation site inhibitors, protease inhibitors, and antisense oligonucleotides show promise in slowing the progression of this disease. A better understanding of these small molecule inhibitors and how they target various extra- and intracellular signaling pathways may eventually lead to a cure for GBM.
多形性胶质母细胞瘤（GBM）是最常见的侵袭性原发性脑肿瘤之一。尽管在手术切除、新型神经成像程序以及最新的辅助放疗和化疗方面取得了进展，但诊断后的中位生存期约为12至14个月。靶向迁移的GBM细胞是对抗这种毁灭性癌症的关键研究策略。虽然绝大多数原发性肿瘤灶可以通过手术切除，但这些迁移细胞是其普遍复发的原因。目前正在探索多种策略和技术来靶向迁移的胶质瘤细胞，小分子抑制剂是研究最广泛的之一。小分子抑制剂，如蛋白激酶抑制剂、磷酸化位点抑制剂、蛋白酶抑制剂和反义寡核苷酸，在减缓这种疾病的进展方面显示出前景。更好地了解这些小分子抑制剂及其如何靶向各种细胞外和细胞内信号通路，最终可能会治愈GBM。
